Idarubicinol myelotoxicity: a comparison of in vitro data with clinical outcome in patients treated with high-dose idarubicin
Open Access
- 1 February 2000
- journal article
- research article
- Published by Springer Nature in British Journal of Cancer
- Vol. 82 (3) , 524-528
- https://doi.org/10.1054/bjoc.1999.0957
Abstract
No abstract availableKeywords
This publication has 21 references indexed in Scilit:
- Hematotoxicity on human bone marrow- and umbilical cord blood-derived progenitor cells and in vitro therapeutic index of methoxymorpholinyldoxorubicin and its metabolitesCancer Chemotherapy and Pharmacology, 1998
- Predicting hematological toxicity (myelosuppression) of cytotoxic drug therapy from in vitro testsAnnals of Oncology, 1998
- Anthracyclines and their C-13 alcohol metabolites: growth inhibition and DNA damage following incubation with human tumor cells in cultureCancer Chemotherapy and Pharmacology, 1992
- Anthracyclines added to the conditioning regimen for allogeneic bone marrow transplantation are associated with a slower haematopoietic recovery.1989
- Comparative cytotoxicity, DNA synthesis inhibition and drug incorporation of eight anthracyclines in a model of doxorubicin-sensitive and -resistant rat glioblastoma cellsBiochemical Pharmacology, 1989
- Extracellular matrix and the hematopoietic microenvironment.1988
- A phase II study of idarubicin (4-demethoxydaunorubicin) in advanced myelomaEuropean Journal of Cancer and Clinical Oncology, 1988
- Effect of daunorubicin, carminomycin, idarubicin and 4-demethoxydaunorubicinol against human normal myeloid stem cells and human malignant cells In vitroEuropean Journal of Cancer and Clinical Oncology, 1987
- ACTIVITY AND DISTRIBUTION OF IV AND ORAL 4-DEMETHOXYDAUNORUBICIN IN MURINE EXPERIMENTAL-TUMORS1984
- Cleavage of DNA by mammalian DNA topoisomerase II.Journal of Biological Chemistry, 1983